• Two of the five Zelnorm patients had known gallstone disease before taking the drug.

    FORBES: Crisis in the Cabinet

  • Now it is up to the company's U.S. sales force to make Zelnorm deliver on its promise.

    FORBES

  • Lotronex was for preventing diarrhea, not constipation, but the doctors still may be shy about prescribing Zelnorm.

    FORBES: Novartis Calls Wonder Woman

  • Approval for Zelnorm, a treatment for painful constipation known as irritable bowel syndrome, was delayed on safety concerns.

    FORBES: Magazine Article

  • Novartis had high hopes for Zelnorm, a new drug it put up for FDA approval two years ago.

    FORBES: Crisis in the Cabinet

  • Graves has compared Zelnorm prescriptions to other drugs where drugmakers had to convince doctors to treat heretofore unrecognized diseases.

    FORBES: Novartis Calls Wonder Woman

  • Carter won't mention Zelnorm by name and Novartis is funding the relatively inexpensive campaign through the nonprofit Society for Women's Health Research.

    FORBES: Magazine Article

  • Zelnorm "is a loss, but we will overcome it, " says Vasella, who hopes to get the drug back on the market eventually.

    FORBES: Big Bucks

  • But Zelnorm is the only treatment approved for IBS marked by constipation.

    FORBES: Magazine Article

  • Eli Lilly's Zyprexa, Glaxo's Zantac and Novartis' Zelnorm are all GPCR-related drugs.

    FORBES: Magazine Article

  • The long saga of Novartis' Zelnorm underscores the frustrations of drug firms.

    FORBES: Crisis in the Cabinet

  • Big, headline-grabbing drug withdrawals that affect millions of patients, like those of Baycol, Vioxx, and Zelnorm, could become a thing of the past.

    FORBES: The End Of Drug Withdrawals?

  • But Vasella is considerably less kind to consumer interest groups like Sidney Wolfe's Public Citizen, which jumped on Zelnorm as a potentially dangerous drug.

    FORBES: Novartis' Potential Blockbuster Zelnorm Approved

  • Zelnorm, a Novartis drug for painful bowel symptoms, was pulled from the market because of another meta-analysis that showed an increased risk of heart attacks.

    FORBES: A Consumer's Guide To Medical Jargon

  • On Friday, the Food and Drug Administration asked Novartis to pull its heavily advertised constipation drug, Zelnorm, after finding a potential link to heart problems.

    FORBES: Magazine Article

  • That delayed Zelnorm's approval in the U.S. by a full year.

    FORBES

  • Zelnorm's approval was delayed because, although the drug seemed to work, regulators noticed a few cases where patients reported gallbladder problems, some of which required surgery.

    FORBES: Novartis' Potential Blockbuster Zelnorm Approved

  • "This study provides further evidence that Zelnorm is a safe and effective treatment for IBS patients, who suffer with abdominal pain, bloating and constipation, " said John F.

    FORBES: Novartis Pushes Ahead On Pipeline Snags

  • But in order to make Zelnorm a blockbuster, Novartis needs to get patients to go to the doctor and ask for help for their irritable bowel disorder.

    FORBES: Novartis Calls Wonder Woman

  • In the past three months the FDA has slapped cautionary labels on sleeping pills and yanked Novartis' constipation drug Zelnorm after that company's analysis showed heart problems.

    FORBES: Magazine Article

  • In June, the FDA had sent the company a "not approvable" letter regarding Zelnorm, saying that further studies would need to be conducted before it could be approved.

    FORBES: Magazine Article

  • The message: If a woman has abdominal pain, bloating and constipation ("the ABC's of IBS"), she should go see a doctor because a new treatment (Zelnorm) is available.

    FORBES: Magazine Article

  • Kurt Graves , Novartis' general manager of U.S. commercial operations, says he expects the campaign to help get women into doctors' offices--and that will help drive Zelnorm sales.

    FORBES: Novartis Calls Wonder Woman

  • Zelnorm, formerly known as Zelmac, treats irritable bowel disorder (IBS)--a combination of constipation, stomach pain and other severe symptoms that affects up to 15% of the population, mostly women.

    FORBES: Novartis Pushes Ahead On Pipeline Snags

  • Eli Lilly (nyse: LLY - news - people )'s Zyprexa, Glaxo's Zantac and Novartis (nyse: NVS - news - people )' Zelnorm are all GPCR-related drugs.

    FORBES: The Next Fat Pill

  • But Novartis was able to get the drug approved by carefully going back over the data with the FDA and demonstrating that the gallbladder surgeries did not appear to be caused by Zelnorm.

    FORBES

  • But today Zelnorm still isn't on the market.

    FORBES: Crisis in the Cabinet

  • In the past two days, Novartis (nyse: NVS - news - people) has quietly released new information about both medications, set a new timetable for getting Xolair approved and published new data on Zelnorm.

    FORBES: Magazine Article

  • In the past three months the FDA has slapped cautionary labels on sleeping pills and yanked Novartis (nyse: NVS - news - people )' constipation drug Zelnorm after that company's analysis showed heart problems.

    FORBES: Lynch 'Em

  • The Zelnorm trends may still be encouraging.

    FORBES: Magazine Article

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定